8 Analysts Have This to Say About Crinetics Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Crinetics Pharmaceuticals (NASDAQ:CRNX) received 8 analyst ratings in the last quarter, with an average price target of $41.25, representing an upside from the current price of $30.01. The ratings include 2 bullish and 6 somewhat bullish, with no indifferent, somewhat bearish, or bearish ratings. The new average price target is a 6.25% decrease from the previous target of $44.00. Analysts use various methods to rate stocks, and their predictions can influence trading decisions.
November 20, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals has a positive outlook from analysts with 8 favorable ratings and an average price target of $41.25, indicating a potential upside from the current price of $30.01.
The unanimous positive ratings from analysts, with no neutral or negative outlooks, suggest a strong consensus on the stock's potential growth. The average price target being significantly higher than the current price could lead to increased investor confidence and a potential short-term price increase for CRNX.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100